Dennis Lo

List of Publications by Year in Descending Order

316 papers	28,859 citations	86 h-index	164 g-index
336 ext. papers	32,815 ext. citations	8.5 avg, IF	6.85 L-index

#	Paper	IF	Citations
316	High-resolution analysis for urinary DNA jagged ends.. *Npj Genomic Medicine*, **2022**, 7, 14	6.2	0
315	Cell-Free DNA Fragmentomics in Liquid Biopsy.. *Diagnostics*, **2022**, 12,	3.8	5
314	Single-molecule sequencing reveals a large population of long cell-free DNA molecules in maternal plasma. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	6
313	Dynamic Changes of Post-Radiotherapy Plasma Epstein-Barr Virus DNA in a Randomized Trial of Adjuvant Chemotherapy Versus Observation in Nasopharyngeal Cancer. *Clinical Cancer Research*, **2021**, 27, 2827-2836	12.9	2
312	Applications of genetic-epigenetic tissue mapping for plasma DNA in prenatal testing, transplantation and oncology. *ELife*, **2021**, 10,	8.9	3
311	Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies. *Science*, **2021**, 372,	33.3	55
310	Cell-free fetal DNA coming in all sizes and shapes. *Prenatal Diagnosis*, **2021**, 41, 1193-1201	3.2	3
309	Fetal mitochondrial DNA in maternal plasma in surrogate pregnancies: Detection and topology. *Prenatal Diagnosis*, **2021**, 41, 368-375	3.2	6
308	Jagged Ends of Urinary Cell-Free DNA: Characterization and Feasibility Assessment in Bladder Cancer Detection. *Clinical Chemistry*, **2021**, 67, 621-630	5.5	4
307	Characteristics of Fetal Extrachromosomal Circular DNA in Maternal Plasma: Methylation Status and Clearance. *Clinical Chemistry*, **2021**, 67, 788-796	5.5	9
306	The Nexus of cfDNA and Nuclease Biology. *Trends in Genetics*, **2021**, 37, 758-770	8.5	12
305	Single Cell and Plasma RNA Sequencing for RNA Liquid Biopsy for Hepatocellular Carcinoma. *Clinical Chemistry*, **2021**, 67, 1492-1502	5.5	2
304	Noninvasive prenatal testing: Advancing through a virtuous circle of science, technology and clinical applications. *Prenatal Diagnosis*, **2021**, 41, 1190-1192	3.2	2
303	Nuclease deficiencies alter plasma cell-free DNA methylation profiles. *Genome Research*, **2021**, 31, 2008-2021	9.7	2
302	Genome-wide detection of cytosine methylation by single molecule real-time sequencing. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	13
301	Towards multi-cancer screening using liquid biopsies. *Nature Reviews Clinical Oncology*, **2020**, 17, 525-526	69.4	4
300	Sequencing Analysis of Plasma Epstein-Barr Virus DNA Reveals Nasopharyngeal Carcinoma-Associated Single Nucleotide Variant Profiles. *Clinical Chemistry*, **2020**, 66, 598-605	5.5	5

299	Plasma DNA End-Motif Profiling as a Fragmentomic Marker in Cancer, Pregnancy, and Transplantation. *Cancer Discovery*, **2020**, 10, 664-673	24.4	42
298	Molecular Diagnostics: Going from Strength to Strength. *Clinical Chemistry*, **2020**, 66, 1-2	5.5	1
297	The Biology of Cell-free DNA Fragmentation and the Roles of DNASE1, DNASE1L3, and DFFB. *American Journal of Human Genetics*, **2020**, 106, 202-214	11	45
296	Early Detection of Cancer: Evaluation of MR Imaging Grading Systems in Patients with Suspected Nasopharyngeal Carcinoma. *American Journal of Neuroradiology*, **2020**, 41, 515-521	4.4	10
295	Cell-Free DNA Fragmentomics: The New "Omics" on the Block. *Clinical Chemistry*, **2020**, 66, 1480-1484	5.5	4
294	Identification and characterization of extrachromosomal circular DNA in maternal plasma. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 1658-1665	11.5	36
293	Plasma DNA Profile Associated with DNASE1L3 Gene Mutations: Clinical Observations, Relationships to Nuclease Substrate Preference, and In Vivo Correction. *American Journal of Human Genetics*, **2020**, 107, 882-894	11	14
292	Detection and characterization of jagged ends of double-stranded DNA in plasma. *Genome Research*, **2020**, 30, 1144-1153	9.7	23
291	Screening of Fetal Chromosomal Aneuploidy by Noninvasive Prenatal Testing: From Innovation to Setting Public Health Agendas to Potential Impact on Other Fields. *Clinical Chemistry*, **2020**, 66, 25-28	5.5	4
290	Plasma Epstein-Barr virus DNA as an archetypal circulating tumour DNA marker. *Journal of Pathology*, **2019**, 247, 641-649	9.4	30
289	Liver-derived cell-free nucleic acids in plasma: Biology and applications in liquid biopsies. *Journal of Hepatology*, **2019**, 71, 409-421	13.4	17
288	Noninvasive Detection of Bladder Cancer by Shallow-Depth Genome-Wide Bisulfite Sequencing of Urinary Cell-Free DNA for Methylation and Copy Number Profiling. *Clinical Chemistry*, **2019**, 65, 927-936	5.5	20
287	Orientation-aware plasma cell-free DNA fragmentation analysis in open chromatin regions informs tissue of origin. *Genome Research*, **2019**, 29, 418-427	9.7	81
286	Methylation analysis of plasma DNA informs etiologies of Epstein-Barr virus-associated diseases. *Nature Communications*, **2019**, 10, 3256	17.4	30
285	Topologic Analysis of Plasma Mitochondrial DNA Reveals the Coexistence of Both Linear and Circular Molecules. *Clinical Chemistry*, **2019**, 65, 1161-1170	5.5	9
284	Enrichment of fetal and maternal long cell-free DNA fragments from maternal plasma following DNA repair. *Prenatal Diagnosis*, **2019**, 39, 88-99	3.2	6
283	deletion causes aberrations in length and end-motif frequencies in plasma DNA. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 641-649	11.5	70
282	Noninvasive Prenatal Testing for Genetic Diseases **2019**, 597-625		0

281	Ambient Temperature and Screening for Nasopharyngeal Cancer. *New England Journal of Medicine*, **2018**, 378, 962-963	59.2	14
280	Noninvasive reconstruction of placental methylome from maternal plasma DNA: Potential for prenatal testing and monitoring. *Prenatal Diagnosis*, **2018**, 38, 196-203	3.2	15
279	Prospective evaluation of plasma Epstein-Barr virus DNA clearance and fluorodeoxyglucose positron emission scan in assessing early response to chemotherapy in patients with advanced or recurrent nasopharyngeal carcinoma. *British Journal of Cancer*, **2018**, 118, 1051-1055	8.7	13
278	Liver- and Colon-Specific DNA Methylation Markers in Plasma for Investigation of Colorectal Cancers with or without Liver Metastases. *Clinical Chemistry*, **2018**, 64, 1239-1249	5.5	47
277	DNase1 Does Not Appear to Play a Major Role in the Fragmentation of Plasma DNA in a Knockout Mouse Model. *Clinical Chemistry*, **2018**, 64, 406-408	5.5	24
276	Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). *Journal of Clinical Oncology*, **2018**, 36, 1412-1418	2.2	185
275	Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial. *Journal of Clinical Oncology*, **2018**, JCO2018777847	2.2	90
274	Circulating Nucleic Acids for Prenatal Diagnostics **2018**, 283-294		
273	Single-cell transcriptomics reveal that PD-1 mediates immune tolerance by regulating proliferation of regulatory T cells. *Genome Medicine*, **2018**, 10, 71	14.4	22
272	Preferred end coordinates and somatic variants as signatures of circulating tumor DNA associated with hepatocellular carcinoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E10925-E10933	11.5	73
271	Fetal DNA in Maternal Plasma: An Amazing Two Decades **2018**, 3-5		
270	Sequencing-based counting and size profiling of plasma Epstein-Barr virus DNA enhance population screening of nasopharyngeal carcinoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E5115-E5124	11.5	75
269	Size-tagged preferred ends in maternal plasma DNA shed light on the production mechanism and show utility in noninvasive prenatal testing. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E5106-E5114	11.5	72
268	Combined Count- and Size-Based Analysis of Maternal Plasma DNA for Noninvasive Prenatal Detection of Fetal Subchromosomal Aberrations Facilitates Elucidation of the Fetal and/or Maternal Origin of the Aberrations. *Clinical Chemistry*, **2017**, 63, 495-502	5.5	11
267	Gestational Age Assessment by Methylation and Size Profiling of Maternal Plasma DNA: A Feasibility Study. *Clinical Chemistry*, **2017**, 63, 606-608	5.5	10
266	Universal Haplotype-Based Noninvasive Prenatal Testing for Single Gene Diseases. *Clinical Chemistry*, **2017**, 63, 513-524	5.5	66
265	Genomewide bisulfite sequencing reveals the origin and time-dependent fragmentation of urinary cfDNA. *Clinical Biochemistry*, **2017**, 50, 496-501	3.5	42
264	COFFEE: control-free noninvasive fetal chromosomal examination using maternal plasma DNA. *Prenatal Diagnosis*, **2017**, 37, 336-340	3.2	13

263	Noninvasive detection of -related inversions and sequence variants in maternal plasma of hemophilia carriers. *Blood*, **2017**, 130, 340-347	2.2	37
262	Single-Stranded DNA Library Preparation Preferentially Enriches Short Maternal DNA in Maternal Plasma. *Clinical Chemistry*, **2017**, 63, 1031-1037	5.5	18
261	Integrative single-cell and cell-free plasma RNA transcriptomics elucidates placental cellular dynamics. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, E7786-E7795	11.5	137
260	Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer. *New England Journal of Medicine*, **2017**, 377, 513-522	59.2	338
259	DNA of Erythroid Origin Is Present in Human Plasma and Informs the Types of Anemia. *Clinical Chemistry*, **2017**, 63, 1614-1623	5.5	44
258	A multicenter randomized controlled trial (RCT) of adjuvant chemotherapy (CT) in nasopharyngeal carcinoma (NPC) with residual plasma EBV DNA (EBV DNA) following primary radiotherapy (RT) or chemoradiation (CRT).. *Journal of Clinical Oncology*, **2017**, 35, 6002-6002	2.2	8
257	Prenatal Diagnosis Innovation: Genome Sequencing of Maternal Plasma. *Annual Review of Medicine*, **2016**, 67, 419-32	17.4	75
256	Tracing the tissue of origin of plasma DNA-feasibility and implications. *Annals of the New York Academy of Sciences*, **2016**, 1376, 14-7	6.5	7
255	Cell-free DNA in maternal plasma and serum: A comparison of quantity, quality and tissue origin using genomic and epigenomic approaches. *Clinical Biochemistry*, **2016**, 49, 1379-1386	3.5	43
254	Second generation noninvasive fetal genome analysis reveals de novo mutations, single-base parental inheritance, and preferred DNA ends. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, E8159-E8168	11.5	99
253	Noninvasive Prenatal Diagnosis of Congenital Adrenal Hyperplasia. *Endocrine Development*, **2016**, 30, 37-41		5
252	Theranos Session at the 2016 AACC Annual Scientific Meeting & Clinical Lab Expo: Expectations, Impressions, and Takeaways. *journal of applied laboratory medicine, The*, **2016**, 1, 329-338	2	1
251	FetalQuant: accurate quantification of fetal DNA fraction by shallow-depth sequencing of maternal plasma DNA. *Npj Genomic Medicine*, **2016**, 1, 16013	6.2	22
250	Noninvasive prenatal testing complicated by maternal malignancy: new tools for a complex problem. *Npj Genomic Medicine*, **2016**, 1, 15002	6.2	3
249	The Long and Short of Circulating Cell-Free DNA and the Ins and Outs of Molecular Diagnostics. *Trends in Genetics*, **2016**, 32, 360-371	8.5	188
248	Noninvasive Prenatal Screening for Genetic Diseases Using Massively Parallel Sequencing of Maternal Plasma DNA. *Cold Spring Harbor Perspectives in Medicine*, **2015**, 5, a023085	5.4	41
247	Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, E5503-12	11.5	391
246	Noninvasive prenatal testing by nanopore sequencing of maternal plasma DNA: feasibility assessment. *Clinical Chemistry*, **2015**, 61, 1305-6	5.5	30

245	Noninvasive prenatal diagnosis: from dream to reality. *Clinical Chemistry*, **2015**, 61, 32-7	5.5	11
244	Molecular diagnostics: a revolution in progress. *Clinical Chemistry*, **2015**, 61, 1-3	5.5	16
243	Noninvasive fetal genomic, methylomic, and transcriptomic analyses using maternal plasma and clinical implications. *Trends in Molecular Medicine*, **2015**, 21, 98-108	11.5	24
242	Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, E1317-25	11.5	392
241	Maternal plasma RNA sequencing for genome-wide transcriptomic profiling and identification of pregnancy-associated transcripts. *Clinical Chemistry*, **2014**, 60, 954-62	5.5	62
240	Size-based molecular diagnostics using plasma DNA for noninvasive prenatal testing. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 8583-8	11.5	181
239	Noninvasive prenatal diagnosis of congenital adrenal hyperplasia using cell-free fetal DNA in maternal plasma. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, E1022-30	5.6	210
238	Plasma DNA aberrations in systemic lupus erythematosus revealed by genomic and methylomic sequencing. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, E5302-11	11.5	79
237	Maternal plasma fetal DNA fractions in pregnancies with low and high risks for fetal chromosomal aneuploidies. *PLoS ONE*, **2014**, 9, e88484	3.7	78
236	Single-nucleotide polymorphism (SNP) of excision repair cross complementation group 1 (ERCC1) in nasopharynx cancer (NPC): A companion biomarker study to Hong Kong NPC Study Group 0502 trial.. *Journal of Clinical Oncology*, **2014**, 32, 6029-6029	2.2	1
235	Methy-Pipe: an integrated bioinformatics pipeline for whole genome bisulfite sequencing data analysis. *PLoS ONE*, **2014**, 9, e100360	3.7	38
234	Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program. *Cancer*, **2013**, 119, 1838-44	6.4	112
233	The potential clinical utility of serial plasma albumin mRNA monitoring for the post-liver transplantation management. *Clinical Biochemistry*, **2013**, 46, 1313-9	3.5	5
232	Noninvasive prenatal methylomic analysis by genomewide bisulfite sequencing of maternal plasma DNA. *Clinical Chemistry*, **2013**, 59, 1583-94	5.5	107
231	Non-invasive prenatal testing using massively parallel sequencing of maternal plasma DNA: from molecular karyotyping to fetal whole-genome sequencing. *Reproductive BioMedicine Online*, **2013**, 27, 593-8	4	38
230	A new era in prenatal diagnosis: the use of cell-free fetal DNA in maternal circulation for detection of chromosomal aneuploidies. *Clinical Chemistry*, **2013**, 59, 1151-9	5.5	18
229	Noninvasive prenatal determination of twin zygosity by maternal plasma DNA analysis. *Clinical Chemistry*, **2013**, 59, 427-35	5.5	55
228	Noninvasive twin zygosity assessment and aneuploidy detection by maternal plasma DNA sequencing. *Prenatal Diagnosis*, **2013**, 33, 675-81	3.2	62

227	Noninvasive Prenatal Diagnosis Using Next-Generation Sequencing **2013**, 241-251		
226	High-resolution profiling of fetal DNA clearance from maternal plasma by massively parallel sequencing. *Clinical Chemistry*, **2013**, 59, 1228-37	5.5	156
225	An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma. *Clinical Cancer Research*, **2013**, 19, 2208-15	12.9	108
224	Noninvasive fetal whole-genome sequencing from maternal plasma: feasibility studies and future directions. *Clinical Chemistry*, **2013**, 59, 601-3	5.5	5
223	Clinical applications of maternal plasma fetal DNA analysis: translating the fruits of 15 years of research. *Clinical Chemistry and Laboratory Medicine*, **2013**, 51, 197-204	5.9	37
222	Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 18761-8	11.5	267
221	Noninvasive fetal RHD genotyping by microfluidics digital PCR using maternal plasma from two alloimmunized women with the variant RHD(IVS3+1G>A) allele. *Prenatal Diagnosis*, **2013**, 33, 1214-6	3.2	18
220	Noninvasive prenatal molecular karyotyping from maternal plasma. *PLoS ONE*, **2013**, 8, e60968	3.7	66
219	Nonhematopoietically derived DNA is shorter than hematopoietically derived DNA in plasma: a transplantation model. *Clinical Chemistry*, **2012**, 58, 549-58	5.5	80
218	Technical concerns about immunoprecipitation of methylated fetal DNA for noninvasive trisomy 21 diagnosis. *Nature Medicine*, **2012**, 18, 1327-8; author reply 1328-9	50.5	13
217	Non-invasive prenatal diagnosis by massively parallel sequencing of maternal plasma DNA. *Open Biology*, **2012**, 2, 120086	7	25
216	Fetal nucleic acids in maternal blood: the promises. *Clinical Chemistry and Laboratory Medicine*, **2012** , 50, 995-8	5.9	5
215	Noninvasive prenatal diagnosis of monogenic diseases by targeted massively parallel sequencing of maternal plasma: application to β-thalassemia. *Clinical Chemistry*, **2012**, 58, 1467-75	5.5	130
214	FetalQuant: deducing fractional fetal DNA concentration from massively parallel sequencing of DNA in maternal plasma. *Bioinformatics*, **2012**, 28, 2883-90	7.2	55
213	Advancing laboratory medicine through innovation: a tale of six inventors. *Clinical Chemistry*, **2012**, 58, 502-10	5.5	4
212	Prenatal assessment of fetal chromosomal and genetic disorders through maternal plasma DNA analysis. *Pathology*, **2012**, 44, 69-72	1.6	8
211	Noninvasive prenatal diagnosis empowered by high-throughput sequencing. *Prenatal Diagnosis*, **2012**, 32, 401-6	3.2	23
210	Proteomic analysis reveals platelet factor 4 and beta-thromboglobulin as prognostic markers in severe acute respiratory syndrome. *Electrophoresis*, **2012**, 33, 1894-900	3.6	18

209	Genomic analysis of fetal nucleic acids in maternal blood. *Annual Review of Genomics and Human Genetics*, **2012**, 13, 285-306	9.7	56
208	Noninvasive fetal trisomy 21 detection using chromosome-selective sequencing: a variation of the molecular counting theme. *Expert Review of Molecular Diagnostics*, **2012**, 12, 329-31	3.8	5
207	Recent advances in the analysis of fetal nucleic acids in maternal plasma. *Current Opinion in Hematology*, **2012**, 19, 462-8	3.3	13
206	Noninvasive prenatal diagnosis of fetal trisomy 21 by allelic ratio analysis using targeted massively parallel sequencing of maternal plasma DNA. *PLoS ONE*, **2012**, 7, e38154	3.7	50
205	High resolution size analysis of fetal DNA in the urine of pregnant women by paired-end massively parallel sequencing. *PLoS ONE*, **2012**, 7, e48319	3.7	67
204	Nucleic Acid Isolation **2012**, 1231-1237		
203	Plasma Nucleic Acids **2012**, 1397-1411		
202	Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. *BMJ, The*, **2011**, 342, c7401	5.9	539
201	Targeted massively parallel sequencing of maternal plasma DNA permits efficient and unbiased detection of fetal alleles. *Clinical Chemistry*, **2011**, 57, 92-101	5.5	104
200	Non-invasive prenatal diagnosis by fetal nucleic acid analysis in maternal plasma: the coming of age. *Seminars in Fetal and Neonatal Medicine*, **2011**, 16, 88-93	3.7	52
199	SFRS7-mediated splicing of tau exon 10 is directly regulated by STOX1A in glial cells. *PLoS ONE*, **2011**, 6, e21994	3.7	10
198	Noninvasive prenatal diagnosis of hemophilia by microfluidics digital PCR analysis of maternal plasma DNA. *Blood*, **2011**, 117, 3684-91	2.2	199
197	Noninvasive prenatal diagnosis of fetal trisomy 18 and trisomy 13 by maternal plasma DNA sequencing. *PLoS ONE*, **2011**, 6, e21791	3.7	215
196	Transplantation monitoring by plasma DNA sequencing. *Clinical Chemistry*, **2011**, 57, 941-2	5.5	16
195	Noninvasive prenatal diagnosis of a case of Down syndrome due to robertsonian translocation by massively parallel sequencing of maternal plasma DNA. *Clinical Chemistry*, **2011**, 57, 917-9	5.5	23
194	The quest for accurate measurement of fetal DNA in maternal plasma. *Clinical Chemistry*, **2011**, 57, 522-3	5.5	5
193	Pregnancy-associated microRNAs in maternal plasma: a channel for fetal-maternal communication?. *Clinical Chemistry*, **2010**, 56, 1656-7	5.5	13
192	Noninvasive prenatal detection of trisomy 21 by an epigenetic-genetic chromosome-dosage approach. *Clinical Chemistry*, **2010**, 56, 90-8	5.5	99

191	Maternal plasma DNA analysis with massively parallel sequencing by ligation for noninvasive prenatal diagnosis of trisomy 21. *Clinical Chemistry*, **2010**, 56, 459-63	5.5	107
190	Synergy of total PLAC4 RNA concentration and measurement of the RNA single-nucleotide polymorphism allelic ratio for the noninvasive prenatal detection of trisomy 21. *Clinical Chemistry*, **2010**, 56, 73-81	5.5	50
189	Aberrant concentrations of liver-derived plasma albumin mRNA in liver pathologies. *Clinical Chemistry*, **2010**, 56, 82-9	5.5	15
188	Serologic antienzyme rate of Epstein-Barr virus DNase-specific neutralizing antibody segregates TNM classification in nasopharyngeal carcinoma. *Journal of Clinical Oncology*, **2010**, 28, 5202-9	2.2	31
187	Epigenetic approaches for the detection of fetal DNA in maternal plasma. *Chimerism*, **2010**, 1, 30-5		18
186	Noninvasive approaches to prenatal diagnosis of hemoglobinopathies using fetal DNA in maternal plasma. *Hematology/Oncology Clinics of North America*, **2010**, 24, 1179-86	3.1	16
185	Epigenetic-genetic chromosome dosage approach for fetal trisomy 21 detection using an autosomal genetic reference marker. *PLoS ONE*, **2010**, 5, e15244	3.7	32
184	Systematic identification of placental epigenetic signatures for the noninvasive prenatal detection of Edwards syndrome. *PLoS ONE*, **2010**, 5, e15069	3.7	24
183	Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus. *Science Translational Medicine*, **2010**, 2, 61ra91	17.5	673
182	Noninvasive prenatal diagnosis in 2020. *Prenatal Diagnosis*, **2010**, 30, 702-3	3.2	18
181	Host-response biomarkers for diagnosis of late-onset septicemia and necrotizing enterocolitis in preterm infants. *Journal of Clinical Investigation*, **2010**, 120, 2989-3000	15.9	123
180	Biology and Diagnostic Applications of Cell-Free Fetal Nucleic Acids in Maternal Plasma. *Nucleic Acids and Molecular Biology*, **2010**, 147-166		2
179	Molecular diagnostics: at the cutting edge of translational research. *Clinical Chemistry*, **2009**, 55, 601	5.5	3
178	Nicht-invasive pr□atale Diagnostik fetaler chromosomaler Aneuploidien mittels Nukleins□reanalyse des m□terlichen Plasmas / Noninvasive prenatal diagnosis of fetal chromosomal aneuploidies by maternal plasma nucleic acid analysis1). *Laboratoriums Medizin*, **2009**, 33, 159-165		
177	Presence of donor-derived DNA and cells in the urine of sex-mismatched hematopoietic stem cell transplant recipients: implication for the transrenal hypothesis. *Clinical Chemistry*, **2009**, 55, 715-22	5.5	24
176	Non-invasive prenatal diagnosis by single molecule counting technologies. *Trends in Genetics*, **2009**, 25, 324-31	8.5	89
175	Development of extraction protocols to improve the yield for fetal RNA in maternal plasma. *Prenatal Diagnosis*, **2009**, 29, 277-9	3.2	8
174	A strategy for identifying circulating placental RNA markers for fetal growth assessment. *Prenatal Diagnosis*, **2009**, 29, 495-504	3.2	28

173	Non-invasive prenatal detection of fetal trisomy 18 by RNA-SNP allelic ratio analysis using maternal plasma SERPINB2 mRNA: a feasibility study. *Prenatal Diagnosis*, **2009**, 29, 1031-7	3.2	27
172	Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. *Clinical Cancer Research*, **2009**, 15, 2076-84	12.9	330
171	Next-generation sequencing of plasma/serum DNA: an emerging research and molecular diagnostic tool. *Clinical Chemistry*, **2009**, 55, 607-8	5.5	30
170	Placenta-derived fetal specific mRNA is more readily detectable in maternal plasma than in whole blood. *PLoS ONE*, **2009**, 4, e5858	3.7	26
169	The prognostic significance of tumor vascular invasion and its association with plasma Epstein-Barr virus DNA, tumor volume and metabolic activity in locoregionally advanced nasopharyngeal carcinoma. *Oral Oncology*, **2008**, 44, 1067-72	4.4	17
168	Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 20458-63	11.5	681
167	Detection and characterization of placental microRNAs in maternal plasma. *Clinical Chemistry*, **2008** , 54, 482-90	5.5	679
166	A microarray approach for systematic identification of placental-derived RNA markers in maternal plasma. *Methods in Molecular Biology*, **2008**, 444, 275-89	1.4	9
165	Quantitative analysis of the transrenal excretion of circulating EBV DNA in nasopharyngeal carcinoma patients. *Clinical Cancer Research*, **2008**, 14, 4809-13	12.9	50
164	Microfluidics digital PCR reveals a higher than expected fraction of fetal DNA in maternal plasma. *Clinical Chemistry*, **2008**, 54, 1664-72	5.5	346
163	Noninvasive prenatal diagnosis of monogenic diseases by digital size selection and relative mutation dosage on DNA in maternal plasma. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 19920-5	11.5	266
162	Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma. *Clinical Chemistry*, **2008**, 54, 1528-36	5.5	124
161	Systematic search for placental DNA-methylation markers on chromosome 21: toward a maternal plasma-based epigenetic test for fetal trisomy 21. *Clinical Chemistry*, **2008**, 54, 500-11	5.5	112
160	Persistent aberrations in circulating DNA integrity after radiotherapy are associated with poor prognosis in nasopharyngeal carcinoma patients. *Clinical Cancer Research*, **2008**, 14, 4141-5	12.9	63
159	A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy. *Cancer Chemotherapy and Pharmacology*, **2008**, 62, 59-64	3.5	67
158	Noninvasive prenatal diagnosis of fetal chromosomal aneuploidies by maternal plasma nucleic acid analysis. *Clinical Chemistry*, **2008**, 54, 461-6	5.5	49
157	Fetal nucleic acids in maternal plasma. *Annals of the New York Academy of Sciences*, **2008**, 1137, 140-3	6.5	12
156	Quantitative aberrations of hypermethylated RASSF1A gene sequences in maternal plasma in pre-eclampsia. *Prenatal Diagnosis*, **2007**, 27, 1212-8	3.2	62

155	Reply to STOX1 is not imprinted and is not likely to be involved in preeclampsia *Nature Genetics*, **2007**, 39, 280-281	36.3	11
154	Plasma placental RNA allelic ratio permits noninvasive prenatal chromosomal aneuploidy detection. *Nature Medicine*, **2007**, 13, 218-23	50.5	312
153	Prenatal diagnosis: progress through plasma nucleic acids. *Nature Reviews Genetics*, **2007**, 8, 71-7	30.1	164
152	Circulating nucleic acids in plasma/serum. *Pathology*, **2007**, 39, 197-207	1.6	126
151	Digital PCR for the molecular detection of fetal chromosomal aneuploidy. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 13116-21	11.5	342
150	Use of a bone marrow transplantation model system to demonstrate the hematopoietic origin of plasma S100B mRNA. *Clinical Chemistry*, **2007**, 53, 1874-6	5.5	6
149	Mass spectrometric detection of an SNP panel as an internal positive control for fetal DNA analysis in maternal plasma. *Clinical Chemistry*, **2007**, 53, 141-2	5.5	24
148	Mass spectrometry-based detection of hemoglobin E mutation by allele-specific base extension reaction. *Clinical Chemistry*, **2007**, 53, 2205-9	5.5	21
147	Detection of restriction enzyme-digested target DNA by PCR amplification using a stem-loop primer: application to the detection of hypomethylated fetal DNA in maternal plasma. *Clinical Chemistry*, **2007**, 53, 1906-14	5.5	26
146	Epigenetic analysis of RASSF1A gene in cell-free DNA in amniotic fluid. *Clinical Chemistry*, **2007**, 53, 796-8	5.5	11
145	Cytokine profile in fatal human immunodeficiency virus tuberculosis Epstein-Barr virus associated hemophagocytic syndrome. *Archives of Internal Medicine*, **2007**, 167, 1901-3		13
144	Comparison of plasma beta-globin DNA and S-100 protein concentrations in acute stroke. *Clinica Chimica Acta*, **2007**, 376, 190-6	6.2	39
143	Genome-wide expression analysis using microarray identified complex signaling pathways modulated by hypoxia in nasopharyngeal carcinoma. *Cancer Letters*, **2007**, 253, 74-88	9.9	46
142	Non-invasive prenatal diagnosis of Down's syndrome. *Lancet, The*, **2007**, 369, 1997	40	9
141	Hypermethylation of RASSF1A in human and rhesus placentas. *American Journal of Pathology*, **2007**, 170, 941-50	5.8	118
140	Clinical applications of plasma Epstein-Barr virus DNA analysis and protocols for the quantitative analysis of the size of circulating Epstein-Barr virus DNA. *Methods in Molecular Biology*, **2006**, 336, 111-21	1.4	7
139	Genomic sequencing of the severe acute respiratory syndrome-coronavirus. *Methods in Molecular Biology*, **2006**, 336, 177-94	1.4	1
138	Noninvasive prenatal detection of fetal trisomy 18 by epigenetic allelic ratio analysis in maternal plasma: Theoretical and empirical considerations. *Clinical Chemistry*, **2006**, 52, 2194-202	5.5	135

137	FETAL NUCLEIC ACIDS IN MATERNAL PLASMA. *Fetal and Maternal Medicine Review*, **2006**, 17, 125-137		
136	Reduced plasma RNA integrity in nasopharyngeal carcinoma patients. *Clinical Cancer Research*, **2006**, 12, 2512-6	12.9	23
135	Molecular analysis of circulating RNA in plasma. *Methods in Molecular Biology*, **2006**, 336, 123-34	1.4	19
134	Setting up a polymerase chain reaction laboratory. *Methods in Molecular Biology*, **2006**, 336, 11-8	1.4	20
133	Time profile of appearance and disappearance of circulating placenta-derived mRNA in maternal plasma. *Clinical Chemistry*, **2006**, 52, 313-6	5.5	41
132	Serum amyloid A is not useful in the diagnosis of severe acute respiratory syndrome. *Clinical Chemistry*, **2006**, 52, 1202-4	5.5	14
131	Serum proteomic fingerprints of adult patients with severe acute respiratory syndrome. *Clinical Chemistry*, **2006**, 52, 421-9	5.5	74
130	Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. *Journal of Clinical Oncology*, **2006**, 24, 5414-8	2.2	285
129	Hypermethylated RASSF1A in maternal plasma: A universal fetal DNA marker that improves the reliability of noninvasive prenatal diagnosis. *Clinical Chemistry*, **2006**, 52, 2211-8	5.5	298
128	Introduction to the polymerase chain reaction. *Methods in Molecular Biology*, **2006**, 336, 1-10	1.4	6
127	Plasma beta-globin DNA as a prognostic marker in chest pain patients. *Clinica Chimica Acta*, **2006**, 368, 110-3	6.2	42
126	Diagnostic developments involving cell-free (circulating) nucleic acids. *Clinica Chimica Acta*, **2006**, 363, 187-96	6.2	136
125	Plasma epigenetic markers for cancer detection and prenatal diagnosis. *Frontiers in Bioscience - Landmark*, **2006**, 11, 2647-56	2.8	14
124	Automated extraction protocol for quantification of SARS-coronavirus RNA in serum: an evaluation study. *BMC Infectious Diseases*, **2006**, 6, 20	4	4
123	Epigenetic Tumor Markers in Plasma and Serum. *Annals of the New York Academy of Sciences*, **2006**, 945, 36-50	6.5	31
122	Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma. *International Journal of Radiation Oncology Biology Physics*, **2006**, 66, 714-20	4	84
121	Fetal DNA in maternal plasma: progress through epigenetics. *Annals of the New York Academy of Sciences*, **2006**, 1075, 74-80	6.5	12
120	Placental RNA in maternal plasma: toward noninvasive fetal gene expression profiling. *Annals of the New York Academy of Sciences*, **2006**, 1075, 96-102	6.5	9

119	Plasma RNA integrity analysis: methodology and validation. *Annals of the New York Academy of Sciences*, **2006**, 1075, 174-8	6.5	8
118	MALDI-TOF mass spectrometry for quantitative, specific, and sensitive analysis of DNA and RNA. *Annals of the New York Academy of Sciences*, **2006**, 1075, 282-7	6.5	11
117	Quantitative Subtyping of Hepatitis B Virus Reveals Complex Dynamics of Ymdd Motif Mutants Development during Long-Term Lamivudine Therapy. *Antiviral Therapy*, **2006**, 11, 1041-1050	1.6	5
116	Recent advances in fetal nucleic acids in maternal plasma. *Journal of Histochemistry and Cytochemistry*, **2005**, 53, 293-6	3.4	42
115	Clinical, virologic and immunologic profiles of a young infant with severe acute respiratory syndrome. *Pediatric Infectious Disease Journal*, **2005**, 24, 567-8	3.4	5
114	Absence of association between angiotensin converting enzyme polymorphism and development of adult respiratory distress syndrome in patients with severe acute respiratory syndrome: a case control study. *BMC Infectious Diseases*, **2005**, 5, 26	4	28
113	A simple and rapid approach for screening of SARS-coronavirus genotypes: an evaluation study. *BMC Infectious Diseases*, **2005**, 5, 87	4	4
112	Tracing SARS-coronavirus variant with large genomic deletion. *Emerging Infectious Diseases*, **2005**, 11, 168-70	10.2	36
111	Fifty years of molecular (DNA/RNA) diagnostics. *Clinical Chemistry*, **2005**, 51, 661-71	5.5	51
110	Comparison of protocols for extracting circulating DNA and RNA from maternal plasma. *Clinical Chemistry*, **2005**, 51, 2209-10	5.5	10
109	Detrimental effect of formaldehyde on plasma RNA detection. *Clinical Chemistry*, **2005**, 51, 1074-6	5.5	4
108	Cell-free DNA in serum and plasma: comparison of ELISA and quantitative PCR. *Clinical Chemistry*, **2005**, 51, 1544-6	5.5	94
107	Effects of preanalytical factors on the molecular size of cell-free DNA in blood. *Clinical Chemistry*, **2005**, 51, 781-4	5.5	140
106	Investigation into the origin and tumoral mass correlation of plasma Epstein-Barr virus DNA in nasopharyngeal carcinoma. *Clinical Chemistry*, **2005**, 51, 2192-5	5.5	39
105	Circulating placental RNA in maternal plasma is associated with a preponderance of 5' mRNA fragments: implications for noninvasive prenatal diagnosis and monitoring. *Clinical Chemistry*, **2005**, 51, 1786-95	5.5	51
104	Lack of dramatic enrichment of fetal DNA in maternal plasma by formaldehyde treatment. *Clinical Chemistry*, **2005**, 51, 655-8	5.5	48
103	Fetal rhesus D mRNA is not detectable in maternal plasma. *Clinical Chemistry*, **2005**, 51, 2210-1	5.5	4
102	Detection of trisomy 21 by quantitative mass spectrometric analysis of single-nucleotide polymorphisms. *Clinical Chemistry*, **2005**, 51, 2358-62	5.5	34

101	Investigation of the genomic representation of plasma DNA in pregnant women by comparative genomic hybridization analysis: a feasibility study. *Clinical Chemistry*, **2005**, 51, 2398-401	5.5	4
100	The 3a protein of severe acute respiratory syndrome-associated coronavirus induces apoptosis in Vero E6 cells. *Journal of General Virology*, **2005**, 86, 1921-1930	4.9	118
99	Detection of the placental epigenetic signature of the maspin gene in maternal plasma. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 14753-8	11.5	286
98	Circulating nucleic acid analysis: diagnostic applications for acute pathologies. *Acta Neurochirurgica Supplementum*, **2005**, 95, 471-4	1.7	6
97	Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody. *Clinical Chemistry*, **2004**, 50, 339-45	5.5	86
96	Quantification of plasma beta-catenin mRNA in colorectal cancer and adenoma patients. *Clinical Cancer Research*, **2004**, 10, 1613-7	12.9	91
95	Effects of filtration on glyceraldehyde-3-phosphate dehydrogenase mRNA in the plasma of trauma patients and healthy individuals. *Clinical Chemistry*, **2004**, 50, 206-8	5.5	16
94	Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA. *Journal of Clinical Oncology*, **2004**, 22, 3053-60	2.2	103
93	ACE2 gene polymorphisms do not affect outcome of severe acute respiratory syndrome. *Clinical Chemistry*, **2004**, 50, 1683-6	5.5	65
92	Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nonnasopharyngeal head and neck carcinomas. *Clinical Cancer Research*, **2004**, 10, 1726-32	12.9	14
91	Free fetal DNA in maternal circulation. *JAMA - Journal of the American Medical Association*, **2004**, 292, 2835; author reply 2835-6	27.4	5
90	Genomic sequencing of a SARS coronavirus isolate that predated the Metropole Hotel case cluster in Hong Kong. *Clinical Chemistry*, **2004**, 50, 231-3	5.5	10
89	Circulating corticotropin-releasing hormone mRNA in maternal plasma: relationship with gestational age and severity of preeclampsia. *Clinical Chemistry*, **2004**, 50, 1851-4	5.5	55
88	Plasma mitochondrial DNA concentrations after trauma. *Clinical Chemistry*, **2004**, 50, 213-6	5.5	74
87	Evaluation of human chorionic gonadotropin beta-subunit mRNA concentrations in maternal serum in aneuploid pregnancies: a feasibility study. *Clinical Chemistry*, **2004**, 50, 1055-7	5.5	40
86	EDTA is a better anticoagulant than heparin or citrate for delayed blood processing for plasma DNA analysis. *Clinical Chemistry*, **2004**, 50, 256-7	5.5	132
85	The biology and diagnostic applications of fetal DNA and RNA in maternal plasma. *Current Topics in Developmental Biology*, **2004**, 61, 81-111	5.3	31
84	Serial analysis of plasma proteomic signatures in pediatric patients with severe acute respiratory syndrome and correlation with viral load. *Clinical Chemistry*, **2004**, 50, 1452-5	5.5	27

83	Recent developments in fetal DNA in maternal plasma. *Annals of the New York Academy of Sciences*, **2004**, 1022, 100-4	6.5	12
82	The biology and diagnostic applications of plasma RNA. *Annals of the New York Academy of Sciences* , **2004**, 1022, 135-9	6.5	25
81	Tissue and cellular tropism of the coronavirus associated with severe acute respiratory syndrome: an in-situ hybridization study of fatal cases. *Journal of Pathology*, **2004**, 202, 157-63	9.4	149
80	Size distributions of maternal and fetal DNA in maternal plasma. *Clinical Chemistry*, **2004**, 50, 88-92	5.5	449
79	MS analysis of single-nucleotide differences in circulating nucleic acids: Application to noninvasive prenatal diagnosis. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 10762-7	11.5	179
78	Distribution of cell-free and cell-associated Epstein-Barr virus (EBV) DNA in the blood of patients with nasopharyngeal carcinoma and EBV-associated lymphoma. *Clinical Chemistry*, **2004**, 50, 1842-5	5.5	12
77	Synthetic peptide studies on the severe acute respiratory syndrome (SARS) coronavirus spike glycoprotein: perspective for SARS vaccine development. *Clinical Chemistry*, **2004**, 50, 1036-42	5.5	28
76	Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. *Journal of Clinical Virology*, **2004**, 31, 304-9	14.5	422
75	Laboratory Diagnosis **2004**, 64-75		
74	Detection of SARS coronavirus RNA in the cerebrospinal fluid of a patient with severe acute respiratory syndrome. *Clinical Chemistry*, **2003**, 49, 2108-9	5.5	189
73	Time course of early and late changes in plasma DNA in trauma patients. *Clinical Chemistry*, **2003**, 49, 1286-91	5.5	164
72	Serial analysis of fetal DNA concentrations in maternal plasma in late pregnancy. *Clinical Chemistry*, **2003**, 49, 678-80	5.5	26
71	Fetal cell-free plasma DNA concentrations in maternal blood are stable 24 hours after collection: analysis of first- and third-trimester samples. *Clinical Chemistry*, **2003**, 49, 195-8	5.5	81
70	Prognostic use of circulating plasma nucleic acid concentrations in patients with acute stroke. *Clinical Chemistry*, **2003**, 49, 562-9	5.5	235
69	Quantitative analysis and prognostic implication of SARS coronavirus RNA in the plasma and serum of patients with severe acute respiratory syndrome. *Clinical Chemistry*, **2003**, 49, 1976-80	5.5	125
68	The concentration of circulating corticotropin-releasing hormone mRNA in maternal plasma is increased in preeclampsia. *Clinical Chemistry*, **2003**, 49, 727-31	5.5	147
67	Non-invasive prenatal diagnosis: on the horizon?. *Pharmacogenomics*, **2003**, 4, 191-200	2.6	12
66	Molecular epidemiology of SARS--from Amoy Gardens to Taiwan. *New England Journal of Medicine*, **2003**, 349, 1875-6	59.2	17

65	Coronavirus genomic-sequence variations and the epidemiology of the severe acute respiratory syndrome. *New England Journal of Medicine*, **2003**, 349, 187-8	59.2	61
64	Fetal DNA in maternal plasma/serum: the first 5 years. *Pediatric Research*, **2003**, 53, 16-7	3.2	8
63	Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. *Cancer*, **2003**, 98, 288-91	6.4	129
62	Cell-free DNA and RNA in plasma as new tools for molecular diagnostics. *Expert Review of Molecular Diagnostics*, **2003**, 3, 785-97	3.8	20
61	Early diagnosis of SARS coronavirus infection by real time RT-PCR. *Journal of Clinical Virology*, **2003**, 28, 233-8	14.5	169
60	The ins and outs of fetal DNA in maternal plasma. *Lancet, The*, **2003**, 361, 193-4	40	16
59	Cell-free nucleic acids in plasma, serum and urine: a new tool in molecular diagnosis. *Annals of Clinical Biochemistry*, **2003**, 40, 122-30	2.2	99
58	Serial analysis of the plasma concentration of SARS coronavirus RNA in pediatric patients with severe acute respiratory syndrome. *Clinical Chemistry*, **2003**, 49, 2085-8	5.5	58
57	Quantitative analysis of pleural fluid cell-free DNA as a tool for the classification of pleural effusions. *Clinical Chemistry*, **2003**, 49, 740-5	5.5	27
56	Origin of plasma cell-free DNA after solid organ transplantation. *Clinical Chemistry*, **2003**, 49, 495-6	5.5	64
55	mRNA of placental origin is readily detectable in maternal plasma. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 4748-53	11.5	327
54	Quantitative analysis of circulating mitochondrial DNA in plasma. *Clinical Chemistry*, **2003**, 49, 719-26	5.5	150
53	Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. *Cancer Research*, **2003**, 63, 2028-32	10.1	151
52	Nasopharyngeal carcinoma in situ (NPCIS)--pathologic and clinical perspectives. *Head and Neck*, **2002**, 24, 989-95	4.2	21
51	Application of fetal DNA in maternal plasma for noninvasive prenatal diagnosis. *Expert Review of Molecular Diagnostics*, **2002**, 2, 32-40	3.8	25
50	Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. *Journal of the National Cancer Institute*, **2002**, 94, 1614-9	9.7	315
49	Male microchimerism in healthy women and women with scleroderma: cells or circulating DNA? A quantitative answer. *Blood*, **2002**, 100, 2845-51	2.2	154
48	Circulating DNA in plasma and serum: biology, preanalytical issues and diagnostic applications. *Clinical Chemistry and Laboratory Medicine*, **2002**, 40, 962-8	5.9	31

47	Prenatal exclusion of beta thalassaemia major by examination of maternal plasma. *Lancet, The*, **2002**, 360, 998-1000	40	238
46	Fetal DNA Clearance from Maternal Plasma Is Impaired in Preeclampsia. *Clinical Chemistry*, **2002**, 48, 2141-2146	5.5	110
45	Differential DNA Methylation between Fetus and Mother as a Strategy for Detecting Fetal DNA in Maternal Plasma. *Clinical Chemistry*, **2002**, 48, 35-41	5.5	165
44	Stability of Endogenous and Added RNA in Blood Specimens, Serum, and Plasma. *Clinical Chemistry*, **2002**, 48, 1647-1653	5.5	437
43	Plasma Nucleic Acids in the Diagnosis and Management of Malignant Disease. *Clinical Chemistry*, **2002**, 48, 1186-1193	5.5	117
42	Predominant Hematopoietic Origin of Cell-free DNA in Plasma and Serum after Sex-mismatched Bone Marrow Transplantation. *Clinical Chemistry*, **2002**, 48, 421-427	5.5	370
41	Noninvasive Prenatal Exclusion of Congenital Adrenal Hyperplasia by Maternal Plasma Analysis: A Feasibility Study. *Clinical Chemistry*, **2002**, 48, 778-780	5.5	127
40	Presence of Filterable and Nonfilterable mRNA in the Plasma of Cancer Patients and Healthy Individuals. *Clinical Chemistry*, **2002**, 48, 1212-1217	5.5	235
39	Differential DNA methylation between fetus and mother as a strategy for detecting fetal DNA in maternal plasma. *Clinical Chemistry*, **2002**, 48, 35-41	5.5	53
38	Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. *Clinical Chemistry*, **2002**, 48, 421-7	5.5	142
37	Circulating cell-free Epstein-Barr virus DNA levels in patients with EBV-associated lymphoid malignancies. *Annals of the New York Academy of Sciences*, **2001**, 945, 80-3	6.5	7
36	Fetomaternal cellular and plasma DNA trafficking: the Yin and the Yang. *Annals of the New York Academy of Sciences*, **2001**, 945, 119-31	6.5	48
35	Technical optimization of RhD zygosity determination by real-time quantitative polymerase chain reaction: implication for fetal RhD status determination by maternal plasma. *Annals of the New York Academy of Sciences*, **2001**, 945, 156-60	6.5	8
34	Detection of mammaglobin mRNA in the plasma of breast cancer patients. *Annals of the New York Academy of Sciences*, **2001**, 945, 192-4	6.5	22
33	Circulating fetal RNA in maternal plasma. *Annals of the New York Academy of Sciences*, **2001**, 945, 207-10	6.5	11
32	Detection of Plasmodium falciparum DNA in plasma. *Annals of the New York Academy of Sciences*, **2001**, 945, 234-8	6.5	33
31	Circulating nucleic acids in plasma and serum: an overview. *Annals of the New York Academy of Sciences*, **2001**, 945, 1-7	6.5	53
30	Quantitative analysis of Epstein-Barr virus DNA in plasma and serum: applications to tumor detection and monitoring. *Annals of the New York Academy of Sciences*, **2001**, 945, 68-72	6.5	48

29	Derivation of a prediction rule for posttraumatic organ failure using plasma DNA and other variables. *Annals of the New York Academy of Sciences*, **2001**, 945, 211-20	6.5	21
28	Prenatal detection of fetal Down's syndrome. *Lancet, The*, **2001**, 357, 959	40	
27	Effects of Blood-Processing Protocols on Fetal and Total DNA Quantification in Maternal Plasma. *Clinical Chemistry*, **2001**, 47, 1607-1613	5.5	290
26	Increased Maternal Plasma Fetal DNA Concentrations in Women Who Eventually Develop Preeclampsia.. *Clinical Chemistry*, **2001**, 47, 137-139	5.5	193
25	Tumor-derived epigenetic changes in the plasma and serum of liver cancer patients. Implications for cancer detection and monitoring. *Annals of the New York Academy of Sciences*, **2000**, 906, 102-5	6.5	22
24	Fetal DNA in maternal plasma. *Annals of the New York Academy of Sciences*, **2000**, 906, 141-7	6.5	25
23	Quantitative analysis of circulating cell-free EpsteinBarr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignancies. *British Journal of Haematology*, **2000**, 111, 239-246	4.5	8
22	Presence of Fetal RNA in Maternal Plasma. *Clinical Chemistry*, **2000**, 46, 1832-1834	5.5	225
21	Plasma DNA as a Prognostic Marker in Trauma Patients. *Clinical Chemistry*, **2000**, 46, 319-323	5.5	289
20	Prenatal detection of fetal Down's syndrome from maternal plasma. *Lancet, The*, **2000**, 356, 1819-20	40	51
19	Quantitative analysis of circulating cell-free Epstein-Barr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignancies. *British Journal of Haematology*, **2000**, 111, 239-46	4.5	85
18	Quantitative Abnormalities of Fetal DNA in Maternal Serum in Preeclampsia. *Clinical Chemistry*, **1999**, 45, 184-188	5.5	435
17	Presence of Donor- and Recipient-derived DNA in Cell-free Urine Samples of Renal Transplantation Recipients: Urinary DNA Chimerism. *Clinical Chemistry*, **1999**, 45, 1741-1746	5.5	87
16	Rapid clearance of fetal DNA from maternal plasma. *American Journal of Human Genetics*, **1999**, 64, 218-24	11	845
15	Fetal RhD genotyping from maternal plasma. *Annals of Medicine*, **1999**, 31, 308-12	1.5	42
14	Maternal plasma fetal DNA as a marker for preterm labour. *Lancet, The*, **1998**, 352, 1904-5	40	220
13	Presence of donor-specific DNA in plasma of kidney and liver-transplant recipients. *Lancet, The*, **1998**, 351, 1329-30	40	220
12	Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. *American Journal of Human Genetics*, **1998**, 62, 768-75	11	1346

11	Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma. *New England Journal of Medicine*, **1998**, 339, 1734-8	59.2	588
10	Setting up a PCR laboratory. *Methods in Molecular Medicine*, **1998**, 16, 11-7		1
9	Artificial Restriction Fragment Length Polymorphism (A-RFLP) Analysis. *Methods in Molecular Medicine*, **1998**, 16, 71-9		1
8	Amplification from archival materials. *Methods in Molecular Medicine*, **1998**, 16, 21-5		
7	Generation of labeled probes by PCR. *Methods in Molecular Medicine*, **1998**, 16, 93-100		
6	PCR-Based Noninvasive Prenatal Diagnosis Using Fetal Cells in Maternal Circulation. *Methods in Molecular Medicine*, **1998**, 16, 265-74		
5	Introduction to the polymerase chain reaction. *Methods in Molecular Medicine*, **1998**, 16, 3-10		2
4	PCR for the detection of minority DNA populations. *Methods in Molecular Medicine*, **1998**, 16, 101-7		
3	Quantitative Assays for Telomerase: Means for Studying the End. *Clinical Chemistry*, **1998**, 44, 2399-2400	5.5	5
2	Presence of fetal DNA in maternal plasma and serum. *Lancet, The*, **1997**, 350, 485-7	40	2164
1	Prenatal Diagnosis through Analysis of Intact Fetal Cells and Cell-Free Nucleic Acids in the Maternal Circulation		978-1000